TriangleTarlatamab (NCT07111507)
Tarlatamab trial for Metastatic Prostate Cancer (NCT07111507). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with metastatic prostate cancer progressing after treatment, with DLL3 on at least half of tumor cells. Newly arising small-cell disease requires prior platinum chemotherapy or ineligibility for it.
The idea: tarlatamab links T cells to DLL3-bearing cancer cells to direct immune attack. A lower starting dose precedes full dosing. Hormone suppression continues except in newly arising small-cell disease. Researchers measure freedom from progression at 24 weeks.
This phase 2 study plans 32 patients. Karen Autio leads at Memorial Sloan Kettering; ten US locations are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.